Cornerstone Pharmaceuticals, operating under the brand Rafael Pharmaceuticals, focuses on developing groundbreaking cancer therapies. The company's flagship compound, devimistat, targets enzymes within the mitochondria of cancer cells, disrupting their energy metabolism. This innovative approach is currently being tested in various clinical trials, ranging from Phase I to Phase III, both as a standalone treatment and in combination with standard drug therapies. The primary aim is to treat patients diagnosed with advanced solid tumors and blood cancers.

Founded in 1999, Cornerstone Pharmaceuticals serves a critical need in the oncology market, particularly for patients with difficult-to-treat cancers. The company collaborates with leading experts and institutions in the field of cancer research and treatment, ensuring that its therapies are at the forefront of medical innovation.

The business model revolves around extensive research and development, followed by clinical trials to validate the efficacy and safety of its compounds. Revenue is generated through partnerships, licensing agreements, and eventually, the commercialization of successful therapies.

Cornerstone Pharmaceuticals operates in the highly specialized and competitive oncology market, aiming to provide life-saving treatments that can significantly improve patient outcomes.

Keywords: cancer therapy, mitochondrial enzymes, devimistat, oncology, solid tumors, blood cancers, clinical trials, advanced cancer, innovative treatment, Rafael Pharmaceuticals.